Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04755283
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-10
First Post:
2021-02-11
Brief Title:
Safety and Tolerability of Abelacimab MAA868 vs Rivaroxaban in Patients With Atrial Fibrillation
Sponsor:
Anthos Therapeutics Inc
Organization:
Anthos Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-11
First Submit QC Date:
February 11 2021
Study First Post Date:
2021-02-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-21
Last Update Post Date:
2024-06-10
Last Update Post Date Type:
ACTUAL